FAR07

FAR07 is an experimental small molecule androgen receptor (AR) antagonist featuring a 4,4-dimethylimidazolidin-2-one pharmacophore. It was developed as part of a chemical series (FAR01-FAR11) aimed at optimizing the flexibility and electronic properties of AR antagonists for the treatment of prostate cancer. Unlike the rigid thiohydantoin structure of second-generation antagonists like enzalutamide, FAR07 utilizes a more flexible imidazolidinone core with an additional methylene spacer to explore the impact of electronic effects and intramolecular non-covalent interactions on binding activity. It is currently in the research phase, with studies focusing on its ability to inhibit AR signaling in androgen-dependent prostate cancer cell lines.